▶ 調査レポート

ソマトスタチンアナログ医薬品のグローバル市場インサイト・予測(~2028年)

• 英文タイトル:Global Somatostatin Analogue Drug Market Insights and Forecast to 2028

QYResearchが調査・発行した産業分析レポートです。ソマトスタチンアナログ医薬品のグローバル市場インサイト・予測(~2028年) / Global Somatostatin Analogue Drug Market Insights and Forecast to 2028 / QY2203B03867資料のイメージです。• レポートコード:QY2203B03867
• 出版社/出版日:QYResearch / 2022年3月11日
• レポート形態:英文、PDF、108ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥725,200 (USD4,900)▷ お問い合わせ
  Multi User¥1,087,800 (USD7,350)▷ お問い合わせ
  Enterprise License¥1,450,400 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症のパンデミックにより、世界のソマトスタチンアナログ医薬品の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にソマトスタチンアナログ医薬品の世界市場のxxx%を占める「オクトレオチド」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「先端巨大症」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
中国のソマトスタチンアナログ医薬品の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのソマトスタチンアナログ医薬品市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパのソマトスタチンアナログ医薬品市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

ソマトスタチンアナログ医薬品のグローバル主要メーカーには、Camurus AB、Chiasma、Ipsen Group、Boehringer Ingelheim International GmbH、Eli Lilly & Co.、F. Hoffmann-La Roche Ltd.、Novartis AG、Pfizer Inc.、Tarveda Therapeutics Inc.、Teva Pharmaceutical Industries Ltd.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

ソマトスタチンアナログ医薬品市場は、種類と用途によって区分されます。世界のソマトスタチンアナログ医薬品市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
オクトレオチド、ランレオチド、パシレオチド

【用途別セグメント】
先端巨大症、神経内分泌腫瘍(NET)、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- ソマトスタチンアナログ医薬品製品概要
- 種類別市場(オクトレオチド、ランレオチド、パシレオチド)
- 用途別市場(先端巨大症、神経内分泌腫瘍(NET)、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界のソマトスタチンアナログ医薬品販売量予測2017-2028
- 世界のソマトスタチンアナログ医薬品売上予測2017-2028
- ソマトスタチンアナログ医薬品の地域別販売量
- ソマトスタチンアナログ医薬品の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別ソマトスタチンアナログ医薬品販売量
- 主要メーカー別ソマトスタチンアナログ医薬品売上
- 主要メーカー別ソマトスタチンアナログ医薬品価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(オクトレオチド、ランレオチド、パシレオチド)
- ソマトスタチンアナログ医薬品の種類別販売量
- ソマトスタチンアナログ医薬品の種類別売上
- ソマトスタチンアナログ医薬品の種類別価格
・用途別市場規模(先端巨大症、神経内分泌腫瘍(NET)、その他)
- ソマトスタチンアナログ医薬品の用途別販売量
- ソマトスタチンアナログ医薬品の用途別売上
- ソマトスタチンアナログ医薬品の用途別価格
・北米市場
- 北米のソマトスタチンアナログ医薬品市場規模(種類別、用途別)
- 主要国別のソマトスタチンアナログ医薬品市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパのソマトスタチンアナログ医薬品市場規模(種類別、用途別)
- 主要国別のソマトスタチンアナログ医薬品市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋のソマトスタチンアナログ医薬品市場規模(種類別、用途別)
- 主要国別のソマトスタチンアナログ医薬品市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米のソマトスタチンアナログ医薬品市場規模(種類別、用途別)
- 主要国別のソマトスタチンアナログ医薬品市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカのソマトスタチンアナログ医薬品市場規模(種類別、用途別)
- 主要国別のソマトスタチンアナログ医薬品市場規模(トルコ、サウジアラビア)
・企業情報
Camurus AB、Chiasma、Ipsen Group、Boehringer Ingelheim International GmbH、Eli Lilly & Co.、F. Hoffmann-La Roche Ltd.、Novartis AG、Pfizer Inc.、Tarveda Therapeutics Inc.、Teva Pharmaceutical Industries Ltd.
・産業チェーン及び販売チャネル分析
- ソマトスタチンアナログ医薬品の産業チェーン分析
- ソマトスタチンアナログ医薬品の原材料
- ソマトスタチンアナログ医薬品の生産プロセス
- ソマトスタチンアナログ医薬品の販売及びマーケティング
- ソマトスタチンアナログ医薬品の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- ソマトスタチンアナログ医薬品の産業動向
- ソマトスタチンアナログ医薬品のマーケットドライバー
- ソマトスタチンアナログ医薬品の課題
- ソマトスタチンアナログ医薬品の阻害要因
・主な調査結果

Somatostatin analogues are drugs that stop your body from making too many hormones. Some neuroendocrine tumours (NETs) make large amounts of hormones that cause a group of symptoms called carcinoid syndrome. Somatostatin analogues are a possible treatment for people with carcinoid syndrome.
Market Analysis and Insights: Global Somatostatin Analogue Drug Market
The global Somatostatin Analogue Drug market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Octreotide accounting for % of the Somatostatin Analogue Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Acromegaly segment is altered to an % CAGR throughout this forecast period.
China Somatostatin Analogue Drug market size is valued at US$ million in 2021, while the North America and Europe Somatostatin Analogue Drug are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Somatostatin Analogue Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Somatostatin Analogue Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Somatostatin Analogue Drug market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Somatostatin Analogue Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Somatostatin Analogue Drug market.
Global Somatostatin Analogue Drug Scope and Market Size
Somatostatin Analogue Drug market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Somatostatin Analogue Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Octreotide
Lanreotide
Pasireotide
Segment by Application
Acromegaly
Neuroendocrine Tumor (NET)
Others
By Company
Camurus AB
Chiasma
Ipsen Group
Boehringer Ingelheim International GmbH
Eli Lilly & Co.
F. Hoffmann-La Roche Ltd.
Novartis AG
Pfizer Inc.
Tarveda Therapeutics Inc.
Teva Pharmaceutical Industries Ltd.
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Somatostatin Analogue Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Octreotide
1.2.3 Lanreotide
1.2.4 Pasireotide
1.3 Market by Application
1.3.1 Global Somatostatin Analogue Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Acromegaly
1.3.3 Neuroendocrine Tumor (NET)
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Somatostatin Analogue Drug Market Perspective (2017-2028)
2.2 Somatostatin Analogue Drug Growth Trends by Region
2.2.1 Somatostatin Analogue Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Somatostatin Analogue Drug Historic Market Size by Region (2017-2022)
2.2.3 Somatostatin Analogue Drug Forecasted Market Size by Region (2023-2028)
2.3 Somatostatin Analogue Drug Market Dynamics
2.3.1 Somatostatin Analogue Drug Industry Trends
2.3.2 Somatostatin Analogue Drug Market Drivers
2.3.3 Somatostatin Analogue Drug Market Challenges
2.3.4 Somatostatin Analogue Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Somatostatin Analogue Drug Players by Revenue
3.1.1 Global Top Somatostatin Analogue Drug Players by Revenue (2017-2022)
3.1.2 Global Somatostatin Analogue Drug Revenue Market Share by Players (2017-2022)
3.2 Global Somatostatin Analogue Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Somatostatin Analogue Drug Revenue
3.4 Global Somatostatin Analogue Drug Market Concentration Ratio
3.4.1 Global Somatostatin Analogue Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Somatostatin Analogue Drug Revenue in 2021
3.5 Somatostatin Analogue Drug Key Players Head office and Area Served
3.6 Key Players Somatostatin Analogue Drug Product Solution and Service
3.7 Date of Enter into Somatostatin Analogue Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Somatostatin Analogue Drug Breakdown Data by Type
4.1 Global Somatostatin Analogue Drug Historic Market Size by Type (2017-2022)
4.2 Global Somatostatin Analogue Drug Forecasted Market Size by Type (2023-2028)
5 Somatostatin Analogue Drug Breakdown Data by Application
5.1 Global Somatostatin Analogue Drug Historic Market Size by Application (2017-2022)
5.2 Global Somatostatin Analogue Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Somatostatin Analogue Drug Market Size (2017-2028)
6.2 North America Somatostatin Analogue Drug Market Size by Type
6.2.1 North America Somatostatin Analogue Drug Market Size by Type (2017-2022)
6.2.2 North America Somatostatin Analogue Drug Market Size by Type (2023-2028)
6.2.3 North America Somatostatin Analogue Drug Market Share by Type (2017-2028)
6.3 North America Somatostatin Analogue Drug Market Size by Application
6.3.1 North America Somatostatin Analogue Drug Market Size by Application (2017-2022)
6.3.2 North America Somatostatin Analogue Drug Market Size by Application (2023-2028)
6.3.3 North America Somatostatin Analogue Drug Market Share by Application (2017-2028)
6.4 North America Somatostatin Analogue Drug Market Size by Country
6.4.1 North America Somatostatin Analogue Drug Market Size by Country (2017-2022)
6.4.2 North America Somatostatin Analogue Drug Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Somatostatin Analogue Drug Market Size (2017-2028)
7.2 Europe Somatostatin Analogue Drug Market Size by Type
7.2.1 Europe Somatostatin Analogue Drug Market Size by Type (2017-2022)
7.2.2 Europe Somatostatin Analogue Drug Market Size by Type (2023-2028)
7.2.3 Europe Somatostatin Analogue Drug Market Share by Type (2017-2028)
7.3 Europe Somatostatin Analogue Drug Market Size by Application
7.3.1 Europe Somatostatin Analogue Drug Market Size by Application (2017-2022)
7.3.2 Europe Somatostatin Analogue Drug Market Size by Application (2023-2028)
7.3.3 Europe Somatostatin Analogue Drug Market Share by Application (2017-2028)
7.4 Europe Somatostatin Analogue Drug Market Size by Country
7.4.1 Europe Somatostatin Analogue Drug Market Size by Country (2017-2022)
7.4.2 Europe Somatostatin Analogue Drug Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Somatostatin Analogue Drug Market Size (2017-2028)
8.2 Asia-Pacific Somatostatin Analogue Drug Market Size by Type
8.2.1 Asia-Pacific Somatostatin Analogue Drug Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Somatostatin Analogue Drug Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Somatostatin Analogue Drug Market Share by Type (2017-2028)
8.3 Asia-Pacific Somatostatin Analogue Drug Market Size by Application
8.3.1 Asia-Pacific Somatostatin Analogue Drug Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Somatostatin Analogue Drug Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Somatostatin Analogue Drug Market Share by Application (2017-2028)
8.4 Asia-Pacific Somatostatin Analogue Drug Market Size by Region
8.4.1 Asia-Pacific Somatostatin Analogue Drug Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Somatostatin Analogue Drug Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Somatostatin Analogue Drug Market Size (2017-2028)
9.2 Latin America Somatostatin Analogue Drug Market Size by Type
9.2.1 Latin America Somatostatin Analogue Drug Market Size by Type (2017-2022)
9.2.2 Latin America Somatostatin Analogue Drug Market Size by Type (2023-2028)
9.2.3 Latin America Somatostatin Analogue Drug Market Share by Type (2017-2028)
9.3 Latin America Somatostatin Analogue Drug Market Size by Application
9.3.1 Latin America Somatostatin Analogue Drug Market Size by Application (2017-2022)
9.3.2 Latin America Somatostatin Analogue Drug Market Size by Application (2023-2028)
9.3.3 Latin America Somatostatin Analogue Drug Market Share by Application (2017-2028)
9.4 Latin America Somatostatin Analogue Drug Market Size by Country
9.4.1 Latin America Somatostatin Analogue Drug Market Size by Country (2017-2022)
9.4.2 Latin America Somatostatin Analogue Drug Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Somatostatin Analogue Drug Market Size (2017-2028)
10.2 Middle East & Africa Somatostatin Analogue Drug Market Size by Type
10.2.1 Middle East & Africa Somatostatin Analogue Drug Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Somatostatin Analogue Drug Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Somatostatin Analogue Drug Market Share by Type (2017-2028)
10.3 Middle East & Africa Somatostatin Analogue Drug Market Size by Application
10.3.1 Middle East & Africa Somatostatin Analogue Drug Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Somatostatin Analogue Drug Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Somatostatin Analogue Drug Market Share by Application (2017-2028)
10.4 Middle East & Africa Somatostatin Analogue Drug Market Size by Country
10.4.1 Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Somatostatin Analogue Drug Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Camurus AB
11.1.1 Camurus AB Company Details
11.1.2 Camurus AB Business Overview
11.1.3 Camurus AB Somatostatin Analogue Drug Introduction
11.1.4 Camurus AB Revenue in Somatostatin Analogue Drug Business (2017-2022)
11.1.5 Camurus AB Recent Developments
11.2 Chiasma
11.2.1 Chiasma Company Details
11.2.2 Chiasma Business Overview
11.2.3 Chiasma Somatostatin Analogue Drug Introduction
11.2.4 Chiasma Revenue in Somatostatin Analogue Drug Business (2017-2022)
11.2.5 Chiasma Recent Developments
11.3 Ipsen Group
11.3.1 Ipsen Group Company Details
11.3.2 Ipsen Group Business Overview
11.3.3 Ipsen Group Somatostatin Analogue Drug Introduction
11.3.4 Ipsen Group Revenue in Somatostatin Analogue Drug Business (2017-2022)
11.3.5 Ipsen Group Recent Developments
11.4 Boehringer Ingelheim International GmbH
11.4.1 Boehringer Ingelheim International GmbH Company Details
11.4.2 Boehringer Ingelheim International GmbH Business Overview
11.4.3 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Introduction
11.4.4 Boehringer Ingelheim International GmbH Revenue in Somatostatin Analogue Drug Business (2017-2022)
11.4.5 Boehringer Ingelheim International GmbH Recent Developments
11.5 Eli Lilly & Co.
11.5.1 Eli Lilly & Co. Company Details
11.5.2 Eli Lilly & Co. Business Overview
11.5.3 Eli Lilly & Co. Somatostatin Analogue Drug Introduction
11.5.4 Eli Lilly & Co. Revenue in Somatostatin Analogue Drug Business (2017-2022)
11.5.5 Eli Lilly & Co. Recent Developments
11.6 F. Hoffmann-La Roche Ltd.
11.6.1 F. Hoffmann-La Roche Ltd. Company Details
11.6.2 F. Hoffmann-La Roche Ltd. Business Overview
11.6.3 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Introduction
11.6.4 F. Hoffmann-La Roche Ltd. Revenue in Somatostatin Analogue Drug Business (2017-2022)
11.6.5 F. Hoffmann-La Roche Ltd. Recent Developments
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Somatostatin Analogue Drug Introduction
11.7.4 Novartis AG Revenue in Somatostatin Analogue Drug Business (2017-2022)
11.7.5 Novartis AG Recent Developments
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Details
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Somatostatin Analogue Drug Introduction
11.8.4 Pfizer Inc. Revenue in Somatostatin Analogue Drug Business (2017-2022)
11.8.5 Pfizer Inc. Recent Developments
11.9 Tarveda Therapeutics Inc.
11.9.1 Tarveda Therapeutics Inc. Company Details
11.9.2 Tarveda Therapeutics Inc. Business Overview
11.9.3 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Introduction
11.9.4 Tarveda Therapeutics Inc. Revenue in Somatostatin Analogue Drug Business (2017-2022)
11.9.5 Tarveda Therapeutics Inc. Recent Developments
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Details
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Introduction
11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Somatostatin Analogue Drug Business (2017-2022)
11.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Somatostatin Analogue Drug Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Octreotide
Table 3. Key Players of Lanreotide
Table 4. Key Players of Pasireotide
Table 5. Global Somatostatin Analogue Drug Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 6. Global Somatostatin Analogue Drug Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Somatostatin Analogue Drug Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Somatostatin Analogue Drug Market Share by Region (2017-2022)
Table 9. Global Somatostatin Analogue Drug Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Somatostatin Analogue Drug Market Share by Region (2023-2028)
Table 11. Somatostatin Analogue Drug Market Trends
Table 12. Somatostatin Analogue Drug Market Drivers
Table 13. Somatostatin Analogue Drug Market Challenges
Table 14. Somatostatin Analogue Drug Market Restraints
Table 15. Global Somatostatin Analogue Drug Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Somatostatin Analogue Drug Revenue Share by Players (2017-2022)
Table 17. Global Top Somatostatin Analogue Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Somatostatin Analogue Drug as of 2021)
Table 18. Ranking of Global Top Somatostatin Analogue Drug Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Somatostatin Analogue Drug Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Somatostatin Analogue Drug Product Solution and Service
Table 22. Date of Enter into Somatostatin Analogue Drug Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Somatostatin Analogue Drug Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Somatostatin Analogue Drug Revenue Market Share by Type (2017-2022)
Table 26. Global Somatostatin Analogue Drug Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Somatostatin Analogue Drug Revenue Market Share by Type (2023-2028)
Table 28. Global Somatostatin Analogue Drug Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Somatostatin Analogue Drug Revenue Share by Application (2017-2022)
Table 30. Global Somatostatin Analogue Drug Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Somatostatin Analogue Drug Revenue Share by Application (2023-2028)
Table 32. North America Somatostatin Analogue Drug Market Size by Type (2017-2022) & (US$ Million)
Table 33. North America Somatostatin Analogue Drug Market Size by Type (2023-2028) & (US$ Million)
Table 34. North America Somatostatin Analogue Drug Market Size by Application (2017-2022) & (US$ Million)
Table 35. North America Somatostatin Analogue Drug Market Size by Application (2023-2028) & (US$ Million)
Table 36. North America Somatostatin Analogue Drug Market Size by Country (2017-2022) & (US$ Million)
Table 37. North America Somatostatin Analogue Drug Market Size by Country (2023-2028) & (US$ Million)
Table 38. Europe Somatostatin Analogue Drug Market Size by Type (2017-2022) & (US$ Million)
Table 39. Europe Somatostatin Analogue Drug Market Size by Type (2023-2028) & (US$ Million)
Table 40. Europe Somatostatin Analogue Drug Market Size by Application (2017-2022) & (US$ Million)
Table 41. Europe Somatostatin Analogue Drug Market Size by Application (2023-2028) & (US$ Million)
Table 42. Europe Somatostatin Analogue Drug Market Size by Country (2017-2022) & (US$ Million)
Table 43. Europe Somatostatin Analogue Drug Market Size by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific Somatostatin Analogue Drug Market Size by Type (2017-2022) & (US$ Million)
Table 45. Asia Pacific Somatostatin Analogue Drug Market Size by Type (2023-2028) & (US$ Million)
Table 46. Asia Pacific Somatostatin Analogue Drug Market Size by Application (2017-2022) & (US$ Million)
Table 47. Asia Pacific Somatostatin Analogue Drug Market Size by Application (2023-2028) & (US$ Million)
Table 48. Asia Pacific Somatostatin Analogue Drug Market Size by Region (2017-2022) & (US$ Million)
Table 49. Asia Pacific Somatostatin Analogue Drug Market Size by Region (2023-2028) & (US$ Million)
Table 50. Latin America Somatostatin Analogue Drug Market Size by Type (2017-2022) & (US$ Million)
Table 51. Latin America Somatostatin Analogue Drug Market Size by Type (2023-2028) & (US$ Million)
Table 52. Latin America Somatostatin Analogue Drug Market Size by Application (2017-2022) & (US$ Million)
Table 53. Latin America Somatostatin Analogue Drug Market Size by Application (2023-2028) & (US$ Million)
Table 54. Latin America Somatostatin Analogue Drug Market Size by Country (2017-2022) & (US$ Million)
Table 55. Latin America Somatostatin Analogue Drug Market Size by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Somatostatin Analogue Drug Market Size by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Somatostatin Analogue Drug Market Size by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Somatostatin Analogue Drug Market Size by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Somatostatin Analogue Drug Market Size by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Somatostatin Analogue Drug Market Size by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Somatostatin Analogue Drug Market Size by Country (2023-2028) & (US$ Million)
Table 62. Camurus AB Company Details
Table 63. Camurus AB Business Overview
Table 64. Camurus AB Somatostatin Analogue Drug Product
Table 65. Camurus AB Revenue in Somatostatin Analogue Drug Business (2017-2022) & (US$ Million)
Table 66. Camurus AB Recent Developments
Table 67. Chiasma Company Details
Table 68. Chiasma Business Overview
Table 69. Chiasma Somatostatin Analogue Drug Product
Table 70. Chiasma Revenue in Somatostatin Analogue Drug Business (2017-2022) & (US$ Million)
Table 71. Chiasma Recent Developments
Table 72. Ipsen Group Company Details
Table 73. Ipsen Group Business Overview
Table 74. Ipsen Group Somatostatin Analogue Drug Product
Table 75. Ipsen Group Revenue in Somatostatin Analogue Drug Business (2017-2022) & (US$ Million)
Table 76. Ipsen Group Recent Developments
Table 77. Boehringer Ingelheim International GmbH Company Details
Table 78. Boehringer Ingelheim International GmbH Business Overview
Table 79. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product
Table 80. Boehringer Ingelheim International GmbH Revenue in Somatostatin Analogue Drug Business (2017-2022) & (US$ Million)
Table 81. Boehringer Ingelheim International GmbH Recent Developments
Table 82. Eli Lilly & Co. Company Details
Table 83. Eli Lilly & Co. Business Overview
Table 84. Eli Lilly & Co. Somatostatin Analogue Drug Product
Table 85. Eli Lilly & Co. Revenue in Somatostatin Analogue Drug Business (2017-2022) & (US$ Million)
Table 86. Eli Lilly & Co. Recent Developments
Table 87. F. Hoffmann-La Roche Ltd. Company Details
Table 88. F. Hoffmann-La Roche Ltd. Business Overview
Table 89. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product
Table 90. F. Hoffmann-La Roche Ltd. Revenue in Somatostatin Analogue Drug Business (2017-2022) & (US$ Million)
Table 91. F. Hoffmann-La Roche Ltd. Recent Developments
Table 92. Novartis AG Company Details
Table 93. Novartis AG Business Overview
Table 94. Novartis AG Somatostatin Analogue Drug Product
Table 95. Novartis AG Revenue in Somatostatin Analogue Drug Business (2017-2022) & (US$ Million)
Table 96. Novartis AG Recent Developments
Table 97. Pfizer Inc. Company Details
Table 98. Pfizer Inc. Business Overview
Table 99. Pfizer Inc. Somatostatin Analogue Drug Product
Table 100. Pfizer Inc. Revenue in Somatostatin Analogue Drug Business (2017-2022) & (US$ Million)
Table 101. Pfizer Inc. Recent Developments
Table 102. Tarveda Therapeutics Inc. Company Details
Table 103. Tarveda Therapeutics Inc. Business Overview
Table 104. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product
Table 105. Tarveda Therapeutics Inc. Revenue in Somatostatin Analogue Drug Business (2017-2022) & (US$ Million)
Table 106. Tarveda Therapeutics Inc. Recent Developments
Table 107. Teva Pharmaceutical Industries Ltd. Company Details
Table 108. Teva Pharmaceutical Industries Ltd. Business Overview
Table 109. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product
Table 110. Teva Pharmaceutical Industries Ltd. Revenue in Somatostatin Analogue Drug Business (2017-2022) & (US$ Million)
Table 111. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Somatostatin Analogue Drug Market Share by Type: 2021 VS 2028
Figure 2. Octreotide Features
Figure 3. Lanreotide Features
Figure 4. Pasireotide Features
Figure 5. Global Somatostatin Analogue Drug Market Share by Application: 2021 VS 2028
Figure 6. Acromegaly Case Studies
Figure 7. Neuroendocrine Tumor (NET) Case Studies
Figure 8. Others Case Studies
Figure 9. Somatostatin Analogue Drug Report Years Considered
Figure 10. Global Somatostatin Analogue Drug Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Somatostatin Analogue Drug Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Somatostatin Analogue Drug Market Share by Region: 2021 VS 2028
Figure 13. Global Somatostatin Analogue Drug Market Share by Players in 2021
Figure 14. Global Top Somatostatin Analogue Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Somatostatin Analogue Drug as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Somatostatin Analogue Drug Revenue in 2021
Figure 16. North America Somatostatin Analogue Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 17. North America Somatostatin Analogue Drug Market Size Market Share by Type (2017-2028)
Figure 18. North America Somatostatin Analogue Drug Market Size Market Share by Application (2017-2028)
Figure 19. North America Somatostatin Analogue Drug Market Size Share by Country (2017-2028)
Figure 20. United States Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Canada Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Somatostatin Analogue Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 23. Europe Somatostatin Analogue Drug Market Size Market Share by Type (2017-2028)
Figure 24. Europe Somatostatin Analogue Drug Market Size Market Share by Application (2017-2028)
Figure 25. Europe Somatostatin Analogue Drug Market Size Share by Country (2017-2028)
Figure 26. Germany Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. France Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. U.K. Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Italy Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Russia Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Nordic Countries Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Somatostatin Analogue Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 33. Asia Pacific Somatostatin Analogue Drug Market Size Market Share by Type (2017-2028)
Figure 34. Asia Pacific Somatostatin Analogue Drug Market Size Market Share by Application (2017-2028)
Figure 35. Asia Pacific Somatostatin Analogue Drug Market Size Share by Region (2017-2028)
Figure 36. China Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Japan Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. South Korea Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Southeast Asia Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. India Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Australia Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 42. Latin America Somatostatin Analogue Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 43. Latin America Somatostatin Analogue Drug Market Size Market Share by Type (2017-2028)
Figure 44. Latin America Somatostatin Analogue Drug Market Size Market Share by Application (2017-2028)
Figure 45. Latin America Somatostatin Analogue Drug Market Size Share by Country (2017-2028)
Figure 46. Mexico Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Brazil Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Middle East & Africa Somatostatin Analogue Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 49. Middle East and Africa Somatostatin Analogue Drug Market Size Market Share by Type (2017-2028)
Figure 50. Middle East and Africa Somatostatin Analogue Drug Market Size Market Share by Application (2017-2028)
Figure 51. Middle East and Africa Somatostatin Analogue Drug Market Size Share by Country (2017-2028)
Figure 52. Turkey Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Saudi Arabia Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. UAE Somatostatin Analogue Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Camurus AB Revenue Growth Rate in Somatostatin Analogue Drug Business (2017-2022)
Figure 56. Chiasma Revenue Growth Rate in Somatostatin Analogue Drug Business (2017-2022)
Figure 57. Ipsen Group Revenue Growth Rate in Somatostatin Analogue Drug Business (2017-2022)
Figure 58. Boehringer Ingelheim International GmbH Revenue Growth Rate in Somatostatin Analogue Drug Business (2017-2022)
Figure 59. Eli Lilly & Co. Revenue Growth Rate in Somatostatin Analogue Drug Business (2017-2022)
Figure 60. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Somatostatin Analogue Drug Business (2017-2022)
Figure 61. Novartis AG Revenue Growth Rate in Somatostatin Analogue Drug Business (2017-2022)
Figure 62. Pfizer Inc. Revenue Growth Rate in Somatostatin Analogue Drug Business (2017-2022)
Figure 63. Tarveda Therapeutics Inc. Revenue Growth Rate in Somatostatin Analogue Drug Business (2017-2022)
Figure 64. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Somatostatin Analogue Drug Business (2017-2022)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed